Australia Dermatology Drugs Market

1. A sample report on Australia Dermatology Drugs Market Analysis

2. This report presents a strategic analysis of the Australia Dermatology Drug Market and a forecast for its development in the medium and long term. It provides a comprehensive overview of the market value, dynamics, segmentation, main players, growth and demand drivers, challenges & future outlook, etc. This is one of the most comprehensive reports about the Australia Dermatology Drug Market, and offers unmatched value, accuracy, and expert insights.

3. Report Scope Report Attribute Details Number of Pages 70-80 Base Year for Estimation 2022 Forecast Period 2023-2030 Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends, Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape, Reimbursement Scenario Report Coverage Quantitative Units Revenue in USD Million/Billion (Mn/Bn) Research Approach Secondary Research (60%), Primary Research (40%) Click on the icon to know the detailed methodology 3 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

4. Table of Content CONTENT PG. NO. 07-20 1. Dermatology Drug Market Overview 1.1. Global Overview 1.2. Australia Overview 1.3. Economic Overview: Australia 1.4. The Burden of Skin Disease in Australia 1.5 Major Dermatological Diseases: Australia 1.6. Psoriasis Overview 1.7. Treatment Pathway for psoriasis 1.8. Dermatology Drug Market in Australia 1.9. Healthcare Scenario in Australia 1.10. Budget of Australia Government for Public Insurance 1.11. Mergers and Acquisitions 21-28 2. Market Size and Forecasting 2.1. Market size and forecasts (Excel and Methodology) 2.2. Market Segmentation 2.2.1. By Drug Class 4 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

5. Table of Content CONTENT PG. NO. 2.2.2. By End User 2.2.3. By Application 2.2.4. By Distribution Channel 29-34 3. Market Dynamics 3.1. Market Growth Drivers 3.2. Market Restraints 35-43 4. Competitive Landscape 4.1. Key Company Profile 4.1.1. Pfizer 4.1.2. XX 4.1.3. XX 4.1.4. XX 4.1.5. XX 4.1.6. XX 5 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

6. Table of Content CONTENT PG. NO. 4.1.7. XX 4.1.8. XX 4.1.9. XX 4.1.10. XX 44-47 5. Reimbursement Scenario 5.1. Reimbursement Regulation in Australia 5.2. Reimbursement Process 48-69 6. Methodology & Scope 6 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

7. Australia Dermatology Drug Market Analysis 1. Market Overview

8. 1.1 Statistics at a Glance: The Scenario of Skin Disease in the World (1/2) Scope of Dermatology Drugs Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ 900 Mn People worldwide are affected by skin disease 4.6 Mn Incident cases of psoriasis globally in 2019 In this section you will get an understanding of the topic, which includes the prevalence of the disease, the application of medical devices, new technology, and other details related to the topic ▪ 80 % Of all skin disease can be attributed to 5 common conditions $75 Bn Is the annual healthcare cost of skin disease in USA In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 125 Mn People worldwide suffer from psoriasis $35.2 Bn Is the annual healthcare burden of psoriasis in USA Illustrative Illustrative 8 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

9. 1.1 Statistics at a Glance: The Scenario of Skin Disease in the World (2/2) Europe ~Revenue to reach $XX Bn by 2027 North America ~ Market Size of $XX Bn Asia -Fastest CAGR Australia Market ~$xx Mn Market Africa ~Market Size of $XX Bn Illustrative Illustrative 9 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

10. 1.2 Australia Overview Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ 54 Mn Is the population of Australia, in 2021 $2.25 Tn is the Gross Domestic Product (GDP) of Australia in 2021 In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 32 Years Is the median age in Australia, in 2021 $9365 Average per capita healthcare expenditure in Australia in 2021 Illustrative Illustrative 10 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

11. 1.3 Economic Overview: Australia Population of Australia, (2020-2030) GDP of Australia, (2020-2030) XX XX XX XX 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F Population Split (2023) In this section you will get an understanding of the demographics of the country/region, which includes the population, GDP, healthcare expenditure and other details related to the topic ▪ By Gender By Age Group In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 0-14 15-24 25-54 55-64 65+ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Female 49% Male 51% Illustrative Illustrative 11 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

12. 1.4 Statistics at a Glance: The Burden of Skin Disease in Australia Overview of Skin Disease Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ 1 Mn People in Australia, suffer from a long- term skin condition 2000 + Deaths due to skin disease in Australia per year In this section you will get an understanding of the topic, which includes the prevalence of the disease, the application of medical devices, new technology, and other details related to the topic in Australia ▪ $9365 Average per capita healthcare expenditure in 2021 31% Population visit dermatologist for treatment of skin disease In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 4.4% Average prevalence of psoriasis in Australia in 2021 $241 Bn Total national health expenditure in 2021 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest Illustrative Illustrative ▪ 12 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

13. 1.5 Major Dermatological Diseases: Australia Skin Cancer Psoriasis Australia has one of the highest incidences of skin cancer globally, with more than 750,000 individuals receiving treatment for this condition annually. ▪ This refers to a persistent autoimmune disorder characterized by the development of red and scaly patches on the skin 4.4% is the average prevalence of psoriasis in Australia in 2021 ▪ ▪ Major Dermatological Diseases Acne Atopic Dermatitis This is a widespread skin condition that arises when hair follicles get blocked with a combination of oil and dead skin cells Prevalence of physician diagnosed acne is 12.8% ▪ This is a prevalent skin condition characterized by dry, itchy, and inflamed skin In the general practice setting in Australia, the approximate lifetime prevalence of atopic dermatitis was recorded at 16.4% ▪ ▪ ▪ Illustrative Illustrative 13 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

14. 1.6 Psoriasis Overview Psoriasis is a persistent autoimmune disorder that primarily affects the skin, resulting in the development of red, raised patches covered with silvery scales It is caused by an overactive immune system that accelerates the skin's cell turnover process, leading to the rapid accumulation of skin cells on the surface and the formation of characteristic lesions It not only affects the skin but can also involve nails and joints, potentially leading to conditions like psoriatic arthritis with joint pain and swelling ▪ ▪ ▪ Signs and Symptoms Types Plaque Psoriasis: Common type, raised red patches with silvery scales Guttate Psoriasis: Small, dot-like lesions, often triggered by infections Inverse Psoriasis: Smooth, red lesions in skin folds Pustular Psoriasis: White blisters with pus, on hands or feet Erythrodermic Psoriasis: Rare, widespread redness, severe itching, skin shedding Psoriatic Arthritis: Joint pain, stiffness, swelling in some with psoriasis Nail Psoriasis: Affects nails, causing pitting, discoloration, abnormal growth ▪ Red, Raised Patches: Elevated red patches on the skin Silvery Scales: Scales covering the red patches Dry, Cracked Skin: Potential dryness, leading to bleeding. Itching or Burning: Common sensations in affected areas Stiff and Swollen Joints: Possible joint stiffness (psoriatic arthritis) Nail Abnormalities: Thickened, pitted, or ridged nails. Soreness or Discomfort: Accompanies psoriasis lesions. Nail Discoloration or Separation: Affects nails, causing discoloration or separation Specific Lesion Areas: Commonly seen on the scalp, elbows, knees, and lower back ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ ▪ Illustrative Illustrative 14 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

15. 1.7 Treatment Pathway for Psoriasis Psoriasis Diagnosis & Disease Assessment Mild Psoriasis BSA ≤ 10% Moderate to severe Psoriasis BSA > 10% Localized Treatment OTC topical Localized steroids Localized Phototherapy Generalized Treatment No Improvement Skip Non-biologics: inadequate treatment response negative impact on quality of life Skip phototherapy: financial constraints inconvenience non-responsive Disease controlled Treatment Adherence Ensure Optimal Adherence Phototherapy Non-biologics Biologics Biologics and/or Phototherapy Non-biologics Biologics Continue Localized Treatment Illustrative Illustrative 15 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

16. 1.8 Dermatology Drug Market in Australia Australia Dermatology Drug Market Forecast, 2022-2030 (in $Bn) 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will get an understanding of the overall Categoryname market in Australia, which includes the market size, current trends and other details related to the topic ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Illustrative Illustrative 16 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

17. 1.9 Healthcare Scenario in Australia Dermatology Drug Development Process: The process of developing a Dermatology drug is complex and involves many stages, from preclinical research to clinical trials to regulatory approval. Here is a simplified diagram of the Dermatology drug development process: Preclinical Research: Researchers identify potential drug candidates and test them in the lab Phase 1 Clinical Trials: Small studies are conducted to test the safety and dosage of the drug in humans Phase 2 Clinical Trials: Larger studies are conducted to test the effectiveness of the drug in treating Dermatology Phase 3 Clinical Trials: Even larger studies are conducted to compare the new drug to standard treatments and evaluate its safety and effectiveness Regulatory Approval: The drug is reviewed by regulatory agencies such as the TGA and approved for use in the Australia market o o o o o TGA has developed several approaches to making drugs available as quickly as possible, while still ensuring their safety and effectiveness. Here are four of these approaches: Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need ▪ Fast Track A process designed to expedite the development and review of drugs which may demonstrate substantial improvement over available therapy Breakthrough Therapy ▪ These regulations allowed drugs for serious conditions that filled an unmet medical need to be approved based on a surrogate endpoint Accelerated Approval ▪ Priority Review A Priority Review designation means TGA’s goal is to take action on an application within 6 months ▪ Illustrative Illustrative 17 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

18. 1.10. Budget of Australia Government for Public Insurance Proposed Budget By Category 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31 Outlays $769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633 Public In Billions Of Dollars $458 $521 $571 $582 $616 $645 $674 $698 $734 $768 $801 $837 $6,926 Private 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7% Public As % Of GDP 2.2% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.5% 2.5% 2.5% 2.5% 2.4% Private National Health Expenditures (NHE) grew 2.7% to $4.3 trillion in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP) ▪ Public spending grew 8.4% to $900.8 billion in 2021, or 21% of total NHE ▪ Private spending grew 9.2% to $734.0 billion in 2021, or 17% of total NHE ▪ Private health insurance spending grew 5.8% to $1,211.4 billion in 2021, or 28% of total NHE ▪ Out of pocket spending grew 10.4% to $433.2 billion in 2021, or 10% of total NHE ▪ Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 billion, or 14% of total NHE ▪ Hospital expenditures grew 4.4% to $1,323.9 billion in 2021, slower than the 6.2% growth in 2020 ▪ Physician and clinical services expenditures grew 5.6% to $864.6 billion in 2021, slower growth than the 6.6% in 2020 ▪ Prescription drug spending increased 7.8% to $378.0 billion in 2021, faster than the 3.7% growth in 2020 ▪ Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7% ▪ Illustrative Illustrative 18 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

19. 1.11. Mergers and Acquisitions (continued) Latest Deals In Australia Amount / Duration Company Name Type Year Key Pointers PharmaLex's merger with Cpharm: PharmaLex, a leading provider of specialized services for the pharma, biotech, and medtech industries, announced its intention to merge with Cpharm, a leading provider of pharmacovigilance and medical services in Australia and New Zealand Cpharm, located in New South Wales, Australia, specializes in delivering pharmacovigilance and medical services to clients in Australia and New Zealand. PharmaLex specializes in offering specialized services to the pharmaceutical, biotech, and medtech sectors. ▪ Merger NA April, 2023 ▪ ▪ Merger of PharmaLex with Cpharm Illustrative Illustrative 19 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

20. 1.11. Mergers and Acquisitions (continued) Latest Deals In Australia Amount / Duration Company Name Type Year Key Pointers Merger March 2023 Merger Jan 2023 20 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

21. Australia Dermatology Drug Market Analysis 2. Market Size and Forecasting

22. 2.1 Market size and forecasts (Excel and Methodology) Australia Dermatology Drug Market Forecast, 2022-2030 Click on the icon to know the methodology and assumption XX Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ XX In this section you will get an understanding of the overall market, which includes the market size, current trends and other details related to the topic ▪ 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ 2023 2024 2025 2026 2027 2028 2029 2030 Major Markets Patient ($Mn) 2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Australia Patient Size ($Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73 % of Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45% Global Market Size ($Bn) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937 Australia Market Size ($Bn) 61 74 84 87 91 95 99 106 Illustrative Illustrative 22 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

23. 2.2 Snapshot of Dermatology Drug Market Segmentation Drug Class End User Application Distributions Channel Anti-infectives Home Care Psoriasis Hospital Pharmacies Corticosteroids Hospital Lichen Sclerosis Retail Pharmacies Atopic Dermatitis (Eczema) Retinoids Dermatology Clinics Online Pharmacies Antirheumatic Acne Calcineurin inhibitors Skin Dermatology Fungal Infection In this section you will get an understanding of the segmentations which will cover the Australia Dermatology Drug Market ▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Illustrative Illustrative 23 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

24. 2.2.1 Market Segmentation: By Drug Class Australia Dermatology Prescriptions Products Market Share Analysis (US$ Mn) 82.3 78.1 75.3 74.8 71.4 70.1 68.9 63.7 63.2 63.2 58.2 58.1 55.2 53.4 45.5 45.2 43.5 42.1 39.1 35.2 34.5 33.5 31.7 28.5 28.3 25.6 23.5 19.3 15.5 12.0 Anti-infective Corticosteroids Retinoids Antirheumatic Calcineurin Inhibitors Illustrative Illustrative 24 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

25. 2.2.2 Market Segmentation: By End User Homecare is the largest segment for Dermatology Drug in Australia and it had a market value of more than 40% in 2022 ▪ Dermatology Drug Market Share, By End User(2022) Use of Dermatology Drug is growing rapidly due to factors the high prevalence of Dermatology and the availability of a large number of Dermatology Drug for treatment ▪ Dermatology Clinics Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Homecare In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic Illustrative Illustrative ▪ Hospital 25 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

26. 2.2.3 Market Segmentation: By Application Psoriasis is the largest segment for Dermatology Drug in Australia and it had a market value of more than 40% in 2022 ▪ Dermatology Drug Market Share, By Application (2022) Use of Dermatology Drug is growing rapidly due to factors the high prevalence of Dermatology and the availability of a large number of Dermatology Drug for treatment ▪ Lichen Sckerosis Skin Cancer Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Acne Psoriasis Fungal Infection In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic Illustrative Illustrative ▪ Eczema 26 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

27. 2.2.4 Market Segmentation: By Distribution Channel Most commonly used distribution channel for Dermatology Drug is Retail pharmacies, as Dermatology Drug are usually administered in hospitals making it convenient for patients to procure them from the hospital pharmacy ▪ Dermatology Drug Market Share, By Distribution Channel (2022) Online Pharmacies Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ Hospital Pharmacies In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Retail Pharmacies Illustrative Illustrative 27 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

28. Australia Dermatology Drug Market Analysis 3. Market Dynamics

29. 3.1 Market Growth Drivers 3.1.1 Different initiatives to increase awareness regarding skin disease , will increase the demand for Dermatology Drugs Initiatives in Dermatology in Australia Australian Government has introduced a multi-million-dollar campaign, "Slip, Slop, Slap, Seek and Slide," aiming to reduce the prevalence of skin cancer in Australia. Skin cancer is recognized as a widespread, expensive, and avoidable form of cancer in the country ▪ Skin Cancer Prevention Campaigns in New South Wales (NSW): The Cancer Institute NSW has been conducting public education initiatives since 2005 to mitigate skin cancer incidence across the state. These campaigns aim to shift public attitudes towards sun safety ▪ SunSmart Tradie Toolbox initiative, a collaboration between the Cancer Council and the Australian Government, focuses on educating and encouraging tradespeople to prioritize sun safety. The campaign aims to increase awareness within the industry regarding the significance of sun protection ▪ 2018 2019 2020 2021 Illustrative Illustrative 29 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

30. 3.1 Market Growth Drivers (continued) 3.1.2 Rising prevalence of skin disease will lead to increased demand for Dermatology medications Prevalence of Diseases in Dermatology in Australia ▪ Increasing prevalence of diverse skin disorders in Australia is a public health issue, as underscored by numerous studies ▪ Psoriasis has a notable prevalence in Australia, impacting 4.4% of the population. It is more frequently observed in adults, with an estimated lifetime prevalence of 2.38% as diagnosed by physicians. ▪ As per a study involving Australian school students, the general occurrence of atopic dermatitis (AD) was 16.3%, demonstrating higher rates in girls compared to boys ▪ Dry skin, or xerosis, was the most prevalent condition, impacting 29.5% of patients, followed by onychomycosis (tinea unguium) at 22.5%, and dermatitis at 8.9% ▪ Furthermore, there has been a yearly rise of up to 6% in the occurrence of skin cancer, particularly non-melanoma skin cancers, over the last three decades Illustrative Illustrative 30 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

31. 3.1 Market Growth Drivers 3.1.3 Increase in Public Healthcare Spending, will increase the demand for Dermatology Drugs National Healthcare Expenditure in Australia XX $ In the fiscal year 2020–21, Australia allocated around $220.9 billion for healthcare expenditures, translating to an average spending of approximately $8,617 per individual, as reported by the Australian Institute of Health and Welfare ▪ XX $ Furthermore, during the 2021–22 fiscal year, Australia's expenditure on health goods and services amounted to an estimated $241.3 billion, averaging around $9,365 per person ▪ The actual increase in overall health spending, adjusted for inflation, was XX % higher than the figures reported for 2020– 2021 ▪ 2020 2021 Illustrative Illustrative 31 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

32. 3.1 Market Growth Drivers 3.1.4 Geriatric population is set to increase 3 Fold in upcoming decade Growing Geriatric Population Disease like psoriasis, eczema are more common in geriatric population ▪ XX % Aging of Australia's population is a result of rising life expectancy and decreasing fertility rates XX % ▪ XX % Population of older Australians, aged 65 and above, rose from 1.0 million (constituting 8.3% of the total population) in 1970 to 2.1 million (12%) in 1995, and this trend is projected to persist with further growth ▪ XX % Australia anticipates an increase in life expectancy, projecting a threefold rise in the population aged over 85 in the coming decades, alongside a doubling of the over-65 demographic ▪ 2020 2021 2022 2023 Illustrative Illustrative 32 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

33. 3.2 Market Restraints 3.2.1 High treatment cost 3.2.3 Regulatory Hurdles 3.2.2 Competition from generic drug market High development costs and the need for ongoing research can result in high pricing for dermatology drugs. Healthcare systems, insurers, and patients may resist high costs, leading to pricing pressures and limited market penetration The average healthcare expenditure per capita in 2021 amounted to $9365 Average healthcare cost for skin cancer is around $11,000 In Australia, approximately 25% of prescriptions submitted to pharmacists are fulfilled with generic medications, highlighting a substantial reliance on non- brand-name drugs within the pharmaceutical landscape of the country ▪ Therapeutic Goods Administration (TGA) oversees the quality, supply, and promotion of medications in Australia ▪ ▪ ▪ Setting prices and securing reimbursement for their products poses challenges for companies in Australia, with the Pharmaceutical Benefits Advisory Committee (PBAC) playing a crucial role in pricing process ▪ Generic drugs constituted over 15% of the total expenditure within the Pharmaceutical Benefits Scheme (PBS) in Australia, underscoring a significant financial allocation toward non-brand-name pharmaceuticals within the national healthcare framework. ▪ ▪ ▪ In terms of approval times, Australia falls in the middle range among global regulators, with a pace slower than the US Food and Drug Administration (FDA) Our analysis will thoroughly investigate the key restraints that may significantly impact business operations and growth. Illustrative Illustrative 33 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

34. Australia Dermatology Drug Market Analysis 4. Competitive Landscape

35. 4.1 Key Players in Australia Dermatology Drug Market MNCs Local Companies Key Note: Here is the list of top 10 companies which will cover in the final report ▪ Mayne Pharma (Foulding) 1 6 Pfizer Each company will have slides for ▪ Overview Key details Offerings Name of products Recent activities/ Press Coverage Distribution and Vendor Partners Mergers, Acquisitions and Collaboration Financials (As per availability) If there are specific companies that you would like to be included in the report, please let us know via email In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Illustrative Illustrative o o 2 7 Sanofi Arrotex o o o 3 8 LEO Pharma AFT Pharmaceuticals o o Neuren o 4 9 Roche Pharmaceuticals ▪ Clarity ▪ 10 5 AbbVie Pharmaceuticals 35 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

36. 4.1.1 Pfizer Solutions offered Founded in: 1849 ▪ Pfizer is a leading global pharmaceutical company which is one of the dominant player in the Australia ▪ It is committed to developing and commercializing premium medicines which are safe, effective as well as affordable ▪ Pfizer's research and development costs for the twelve months ending September 30, 2023, rose by 1.97% compared to the previous year, reaching $11.480 billion HQ: New York, USA ➢ Diagnostics ➢ Biologics and Dermatology Drug Type: Private ➢ Pharmaceuticals Revenue: $100.3 Bn (global) ➢ Veterinary products Website: www.pfizer.com Recent Activity / Press Coverage Some of the Dermatology Drug offered by Pfizer Tofacitinib Treatment for adults with moderate to severe plaque psoriasis Oct 2023: Pfizer has recently received FDA approval for its Dermatology Drug ABRILADA™, which is one of only two Dermatology Drug that are interchangeable with Humira® CIBINQO® (abrocitinib) Treatment of moderate-to-severe atopic dermatitis ABRILADA™ (adalimumab-afzb) Treatment of psoriasis and psoriatic arthritis Oct 2023:Pfizer Australia and BioNTech have received approval from the Therapeutic Goods Administration (TGA) for their monovalent COVID-19 vaccine adapted to the Omicron XBB.1.5 variant Etanercept (Enbrel) Treatment of psoriasis and psoriatic arthritis Illustrative Illustrative 36 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

37. 4.1.1 Pfizer (continued) Latest Deals - Mergers and Acquisitions Amount / Duration Company Name Type Year Key Pointers Pfizer announced that it would acquire Seagen, a global biotechnology company that discovers, develops, and commercializes transformative Dermatology medicines ▪ This acquisition is expected to enhance Pfizer's position the segment of Oncology, with Seagen's medicines, late-stage development programs, and pioneering expertise in Antibody- Drug Conjugates (ADCs) strongly complementing Pfizer's Oncology portfolio ▪ Acquisition $43 Bn Mar, 2023 Seagen Inc. Pfizer acquired Arena Pharmaceuticals, a clinical-stage startup creating novel potential treatments for the treatment of various immuno-inflammatory illnesses ▪ Acquisition $6.7 Bn Mar, 2022 This acquisition granted Pfizer access to Arena's portfolio of potential treatments for the fields of gastrointestinal, dermatology, and cardiology ▪ Arena Pharmaceuticals Illustrative Illustrative 37 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

38. 4.1.1 Pfizer (continued) Revenues ($Bn), 2020-2030 Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ In this section you will the understating of financial overview of the company, which includes revenue forecasting, segment revenue and other key details as per availability ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Breakdown of Net Revenue by Segment, 2023 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 1 2 3 4 Illustrative Illustrative 38 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

39. 4.1.2 Company 2 Solutions offered by Company Founded in: HQ: Type: Revenue: Website: Dermatology Drug Products Recent Activity / Press Coverage Drugs Indications 39 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

40. 4.1.2 Company 2 (continued) Partnerships Ecosystem Major Distribution Partners Major Vendor Partners 40 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

41. 4.1.2 Company 2 (continued) Latest Deals - Mergers and Acquisitions Amount / Duration Company Name Type Year Key Pointers 41 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

42. 4.1.2 Company 2 (continued) Revenues ($Bn), 2020-2030 Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be presented in the final report ▪ xx xx xx In this section you will the understating of financial overview of the company, which includes revenue forecasting, segment revenue and other key details as per availability ▪ 2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F In order to obtain access to all of the information that you are seeking, you will need to purchase the final report ▪ Breakdown of Net Revenue by Segment, 2022 Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ 1 2 3 4 42 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

43. Australia Dermatology Drug Market Analysis 5. Reimbursement Scenario

44. 5.1 Reimbursement Regulation for Dermatology Drug in Australia Coverage Penetration (% Total Population) Source of Funding Spend on Healthcare (%of Current Health Expenditure) 100% 100% 100% 100% 100% 44.0% Government Expenditure 46.0% xx 47.7% xx xx xx 51.0% 51.8% xx Public Healthcare Coverage Private Health Insurance Out of Pocket 38.9% 37.1% 35.6% 31.5% 32.5% Private Coverage Other NA NA 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6%  Public healthcare coverage is provided by the government and includes various programs GDP Growth (yoy) 14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy) Reimbursement Market Trends ▪ Shift towards value-based care has been a significant trend in Australia healthcare system, with payers and providers increasingly focused on improving patient outcomes and reducing costs ▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which incentivize providers to deliver high-quality, cost-effective care Illustrative Illustrative 44 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

45. 5.2 Reimbursement Process The reimbursement process in Australia healthcare system can be complex and can vary depending on the type of healthcare service, the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process: Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient ▪ Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the service provided ▪ Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential errors or fraud ▪ Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service provided, based on the negotiated payment rates or fee schedule ▪ Patient Responsibility: Depending on the patient's insurance coverage, they may be responsible for paying a portion of the cost of the service, such as deductibles, co-payments, or co-insurance In order to obtain access to all of the information that you are seeking, you will need to purchase the final report Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or subject matter of interest ▪ Illustrative Illustrative 45 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

46. 5.2 Reimbursement Process (Continued) The reimbursement process in Australia healthcare system can be complex and can vary depending on the type of healthcare service, the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process: MoH Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient ▪ Market Authorization Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the service provided ▪ Private Payers Public Payers Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential errors or fraud ▪ Health Technology Assessment Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service provided, based on the negotiated payment rates or fee schedule ▪ 1 2 3 Coding Coverage Payment Coding depends on availability code while coverage and payment process decisions are made through an HTA. Illustrative Illustrative 46 A Sample Report on Australia Dermatology Drug Market Analysis I Confidential

47. Australia Dermatology Drug Market Analysis 6. Methodology & Scope

48. A division of

49. Life-sciences Market Research Reports you can trust Insights10 is a healthcare focused market research firm founded with an aim of being an insights driven company in the data driven world and delivering actionable insights that can drive decision and strategy making process for businesses www.insights10.com www.insights10.com

50. Get actionable insights to take informed business decisions A large database of over 30,000 syndicated market research reports in pharmaceuticals and healthcare sector at global, regional as well as country level. We also provide customized research reports tailor made to suit your needs www.insights10.com